从华熙生物(SH688363)与巨子生物(HK02367)在重组胶原蛋白领域的专利厮杀,到爱美客(SZ300896)与江苏吴中(SH600200,目前证券简称*ST苏吴)的代理权争夺,再到新氧甩出童颜针低价牌,纵观2025年下半年,国内医美市场硝烟味愈发浓烈。 从市场规模看,中国医美产业的地位与10年前相比已不再“边缘”,但在去年,“互联网医美第一股”新氧的董事长金星喊出,中国医美机构数量太少,...
Source Link从华熙生物(SH688363)与巨子生物(HK02367)在重组胶原蛋白领域的专利厮杀,到爱美客(SZ300896)与江苏吴中(SH600200,目前证券简称*ST苏吴)的代理权争夺,再到新氧甩出童颜针低价牌,纵观2025年下半年,国内医美市场硝烟味愈发浓烈。 从市场规模看,中国医美产业的地位与10年前相比已不再“边缘”,但在去年,“互联网医美第一股”新氧的董事长金星喊出,中国医美机构数量太少,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.